Kronos Bio Inc Cash Flow Conversion Efficiency
Kronos Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Kronos Bio Inc (KRON) has a cash flow conversion efficiency ratio of -0.161x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.84 Million) by net assets ($79.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kronos Bio Inc (2018–2024)
Cash flow conversion efficiency of Kronos Bio Inc from 2018 to 2024. This chart illustrates how Kronos Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View KRON stock price for real-time trading data and today's change.
Kronos Bio Inc Cash Flow Conversion Ratio Explained
Kronos Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kronos Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kronos Bio Inc ranked by their cash flow conversion efficiency. Also see how much is Kronos Bio Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
City Sports and Recreation Public Company Limited
BK:CSR
|
0.010x |
|
Hexza Corporation Bhd
KLSE:3298
|
0.012x |
|
Bekasi Fajar Industrial Estate
JK:BEST
|
0.001x |
|
Aplisens SA
WAR:APN
|
0.047x |
|
Xin Chio Global Co Ltd
TWO:3171
|
0.084x |
|
Anfield Energy Inc.
NASDAQ:AEC
|
-0.070x |
|
Atinum Investment Co. Ltd
KQ:021080
|
0.098x |
|
US Masters Residential Property Fund
AU:URF
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Kronos Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kronos Bio Inc from 2018 to 2024. Review KRON financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $87.58 Million | $-65.44 Million | -0.747x | -51.25% |
| 2023-12-31 | $159.08 Million | $-78.58 Million | -0.494x | -32.83% |
| 2022-12-31 | $244.50 Million | $-90.93 Million | -0.372x | -8.83% |
| 2021-12-31 | $345.10 Million | $-117.92 Million | -0.342x | -319.59% |
| 2020-12-31 | $465.52 Million | $-37.91 Million | -0.081x | -112.53% |
| 2019-12-31 | $-23.20 Million | $-15.08 Million | 0.650x | -26.37% |
| 2018-12-31 | $-7.30 Million | $-6.44 Million | 0.883x | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more